

---

## BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.  
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

---

NAME: MANZO, TERESA

---

eRA COMMONS USER NAME (credential, e.g., agency login): ManTes

---

POSITION TITLE: Principal Investigator

---

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

---

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date MM/YYYY	FIELD OF STUDY
University of Milan (Milan, Italy)	MS, <i>Summa cum Laude</i>	10/2007	Medical Biotechnology
Vita-Salute San Raffaele University (Milan, Italy)	Ph.D.	07/2012	Immunology
Harvard Medical School (Boston, MA USA)	EMBO Short Term Fellow	05/2012	Immunology and Inflammatory Diseases
University College of London (London, UK)	Postdoctoral	01/2014	Hematopoietic Transplantation and Immunotherapy
Baylor College of Medicine (Houston, TX USA)	Postdoctoral	1/2015	Cancer Immunotherapy
University of Texas MD Anderson Cancer Center (Houston, TX USA)	Senior Postdoctoral	1/2018	Immunometabolism
European Institute of Oncology (Milan, IT)	Principal Investigator		Immunometabolism and Cancer Immunotherapy

---

### A. Personal Statement

The notion that immune system protects against tumor formation and shapes its immunogenicity has always been fascinating to me and, at the same time, it represents a challenge we urge to win to make immunotherapy more effective against cancer and give a new perspective to patients. This is the driving force of our lab, where we bring together concepts at the edges of our current understanding of cytotoxic T cell biology with the ambition to foster new opportunities that could eventually broaden the clinical efficacy of immunotherapy.

In almost 15 years of research experience in the field of Cancer Immunotherapy, I made significant contributions on defining new strategies to overcome immunological tolerance that limits the protective immunity against solid tumors. During my PhD at San Raffaele Scientific Institute, I developed and validated a novel immunotherapeutic strategy able to restore immune competence and allow disease-free survival in a mouse model of prostate cancer (PMID: 27872095; PMID: 23749644; PMID: 21209285; PMID: 24244899; PMID: 20388780; PMID: 32973794). In the attempt to visualize the dynamic of tumor infiltration by intravital microscopy, I was awarded by an EMBO Short Term fellowship and I spent the last part of my PhD training at Harvard-MGH in Boston (PMID: 23313588). Following my interest in determining the factors that influence the GvT and GvHD effects, I joined UCL in London. Here, I consolidated and applied with success my research skills, being responsible for the design, execution and analysis of different projects (PMID: 25404365; PMID: 25904681 ; PMID: 25834108; PMID: 26464217; PMID: 31917684). In 2015, I relocated to Houston as senior Postdoc at MD Anderson Cancer Center, where I led a research project aimed to understand the reason behind the failure of immunotherapy as a valid therapeutic

option for pancreatic cancer. We discovered that metabolic constraints imposed by the PDAC TME suppress CD8 anti-tumor responses by reshaping their metabolism (PMID: 32491160). Our data introduce the concept that tumor-infiltrating CD8+ T cells must retain their metabolic flexibility and adjust in response to the hostile TME to mount an effective anti-tumor response. Nowadays, I'm a Principal Investigator at IEO where I'm leading a team interested in understanding the interplay between T cell metabolism and anti-tumor responses to optimize personalized cancer immunotherapy.

## **B. Positions and Honors**

### **Positions and Employment**

2019-present	Principal Investigator – Head of “Immunometabolism and Cancer Immunotherapy” research unity at IEO – Milan (IT)
2015-2018	Senior Postdoctoral Fellow – MD Anderson Cancer Center – Houston (TX) Understanding the failure of immunotherapy as a therapeutic option for PDAC.
2014-2015	Postdoctoral Fellow – Baylor College of Medicine – Houston (TX) Combining oncolytic viruses and T cell therapy.
2012-2014	Postdoctoral Fellow – University College of London – London (UK) Agonistic co-stimulation and co-inhibitory blockade to reverse CD8 <sup>+</sup> T cell exhaustion.
2007-2012	PhD – San Raffaele Scientific Institute – Milan (IT) Immunotherapy to overcome tolerance against solid tumor.
2011-2012	EMBO Short Term Fellow- Harvard Medical School-Boston (MA) Use of intravital microscopy to visualize mechanisms of tumor aggression.

### **Other Professional Experiences**

2021 -present	Editorial Board: Frontiers in Immunology (section T cell biology).
2021 -present	Journal Reviewer: Frontiers in Oncology.
2018 -present	Faculty member SEMM PhD School

### **Honors**

2008-2007	Academic excellence annual award and thesis discussion award
2008-2012	Ph.D. fellowship by the Italian Ministry of Education and Research for the best five candidates
2012	EMBO Short Term Fellowship
2013	Leukemia and Lymphoma Research (LLR) Fellowship
2018	NIBIT Translational Science Award
2018	SITC Young Investigator Travel Award (2018)
2019- 2023	Start-Up AIRC Grant (2019-2023)
2020	Preclinical reference in CRC program of the Alliance against Cancer
2020	Selected for the annual Best of JEM series 2020
2021	Award to attend SITC's Women in Cancer Immunotherapy Network (WIN)
2021	SITC Young Investigator Travel Award (2021)

### **Professional Membership**

2018-present	Associate Member, Society for Immunotherapy of Cancer's (SITC)
2018-present	Associate Member NIBIT

## **C. Complete List of Published Work**

ORCID ID:	0000-0001-8552-3625
Scopus Author ID	<a href="https://orcid.org/0000-0001-8552-3625">36889860300</a>
Google scholar	<a href="https://scholar.google.com/citations?user=ZwY59ugAAAAJ&amp;hl=en">https://scholar.google.com/citations?user=ZwY59ugAAAAJ&amp;hl=en</a>